在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

美國(guó)MediciNova
MediciNova ，公司是一家公開(kāi)上市的生物制藥公司，側(cè)重于獲取和發(fā)展新的，小分子療法，用于治療疾病的未滿足的需要特別關(guān)注美國(guó)市場(chǎng)。通過(guò)戰(zhàn)略聯(lián)盟與日本主要的制藥公司， MediciNova擁有權(quán)，多元化的投資組合的臨床和臨床前候選產(chǎn)品，每個(gè)MediciNova認(rèn)為有一個(gè)良好的特點(diǎn)和不同的治療資料，有吸引力的商業(yè)潛力和專利資產(chǎn)的說(shuō)法有充分的商業(yè)范圍。 MediciNova的管道包括6個(gè)臨床階段的化合物，用于治療急性加重哮喘，多發(fā)性硬化癥，哮喘，間質(zhì)性膀胱炎，固體腫瘤的癌癥，廣泛性焦慮癥，早產(chǎn)和尿失禁和前兩個(gè)階段的化合物，用于治療血栓性疾病。 MediciNova目前的戰(zhàn)略是集中資源，它的兩個(gè)優(yōu)先候選產(chǎn)品，美國(guó)明尼蘇達(dá)- 221用于治療急性加重哮喘和Mn - 166用于治療多發(fā)性硬化癥，要么追求發(fā)展獨(dú)立的，如果錳- 221 ，或建立戰(zhàn)略合作，以支持進(jìn)一步發(fā)展，如錳166 。 MediciNova將尋求其他產(chǎn)品賺錢(qián)候選人鍵值拐點(diǎn)。

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on its two prioritized product candidates, MN-221 for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations and MN-166 for the treatment of multiple sclerosis, and either pursue development independently, in the case of MN-221, or establish a strategic collaboration to support further development in the United States, in the case of MN-166. MediciNova will seek to monetize its other product candidates at key value inflection points. MediciNova’s executive management team has extensive global development, regulatory and commercial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in San Diego, California, MediciNova today has approximately 25 employees.
?